Experience of olokizumab use in COVID-19 patients
Authors:
- V N AntonovVAV N Antonov
- G L IgnatovaGIG L Ignatova
- O V PribytkovaOPO V Pribytkova
- S S SleptsovaSSS S Sleptsova
- E A StrebkovaESE A Strebkova
- E A KhudyakovaEKE A Khudyakova
- A I SimakovASA I Simakov
- S Y RabetsSRS Y Rabets
- E P TikhonovaETE P Tikhonova
- D Y KurmaevaDKD Y Kurmaeva
- M A PetrushinMPM A Petrushin
- A S MashkovAMA S Mashkov
Open Access
- 15 December 2020
- journal article
- research article
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 92 (12) , 148-154
Abstract
Most subjects with the COVID-19 experience mild to moderate symptoms, but approximately 10% of cases suffer from severe course of disease. IL-6 inhibitors are actively used to neutralize and prevent the cytokine storm. Olokizumab is a humanized monoclonal antibody belonging to the G4/Kappa immunoglobulin isotype that selectively binds to human IL-6 and effectively neutralizes it. Aim.To evaluate the efficacy and safety of Artlegia (olokizumab) for the treatment of subjects with a disease caused by the SARS-COV-2 virus in a real-world clinical setting. Materials and methods.The analysis included data of 610 subjects aged 55.0812.68 years who received olokizumab at a single dose of 160 mg/mL 0.4 mL subcutaneously as a preemptive anti-inflammatory therapy. The comparison group included 511 subjects aged 55.2311.23 years who received standard therapy without IL-6 inhibitors. Control Endpoints: 1. Positive clinical changes on Day 7. 2. Changes in the CRP levels on Days 1, 2, and 7. 3. Duration of oxygen therapy. 4. Number of days in hospital. 5. Number of adverse events. 6. Disease outcome. Results.If a cytokine storm occurs, immune regulatory events will trigger the development of either a protective immune response or an exacerbated inflammatory response. The use of preemptive anti-inflammatory therapy has both a short-term and, most importantly, a long-term effect on the T and B parts of the immune process. These aspects definitely require further research and observation. Conclusion.The use of olokizumab to treat the new COVID-19 coronavirus disease has demonstrated a positive effect on clinical and laboratory parameters. Primarily, it affects the severity of clinical parameters by improving the general condition already on the first day of observation, and decreasing body temperature to normal values. The changes in the C-reactive protein levels show a significant effect of the IL-6 inhibitor on the systemic inflammatory response.Keywords
This publication has 10 references indexed in Scilit:
- A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severityNature Communications, 2020
- COVID-19 cytokine storm: The anger of inflammationCytokine, 2020
- The COVID-19 Cytokine Storm; What We Know So FarFrontiers in Immunology, 2020
- Immune Response, Inflammation, and the Clinical Spectrum of COVID-19Frontiers in Immunology, 2020
- COVID-19: Immunology and treatment optionsClinical Immunology, 2020
- COVID-19 as an Acute Inflammatory DiseaseThe Journal of Immunology, 2020
- COVID‐19 diagnosis and management: a comprehensive reviewJournal of Internal Medicine, 2020
- Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19Allergy, 2020
- Coronavirus infections and immune responsesJournal of Medical Virology, 2020
- Immunopathogenesis of coronavirus infections: implications for SARSNature Reviews Immunology, 2005